https://www.selleckchem.com/products/su6656.html
OBJECTIVES This is a randomized trial adopted to evaluate the safety and efficacy of immunization with specific anti-hepatocellular carcinoma dendritic cells (DCs) in Egyptian patients with advanced hepatocellular carcinoma (HCC) as a treatment or adjuvant therapy in comparison with the traditional therapy. METHODS This study was conducted on 20 HCC patients who were assigned to four groups according to BCLC staging; group I HCC patients (stage received trans-arterial chemoembolization (TACE) and DCs as an adjuvant therapy; group II H
Curtir
Comentario
Compartilhar
